Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, B-Cell, Marginal Zone

Explore clinical trials studying Lymphoma, B-Cell, Marginal Zone. Study availability and eligibility vary by location and protocol.

645 public trials 88 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, B-Cell, Marginal Zone trial results

Active, Not Recruiting

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

NCT03162536

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +41 more
Locations
  • Mayo Clinic Hospital ( Site 0140) Scottsdale, Arizona, United States
  • UCLA Hematology & Oncology ( Site 0017) Los Angeles, California, United States
  • Colorado Blood Cancer Institute ( Site 0225) Denver, Colorado, United States
  • University of Michigan ( Site 0018) Ann Arbor, Michigan, United States
View Trial Details
Active, Not Recruiting

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

NCT01955499

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +21 more
Locations
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada
View Trial Details
Active, Not Recruiting

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

NCT03474744

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Med. Uni Wien AKH, Klinische Abteilung für Onkologie, Innere Medizin I Vienna, Austria
  • St. Josef-Hospital, Medizinische Klinik I Bochum, Germany
  • Johanniter GmbH, Johanniter-Krankenhaus Bonn, Germany
  • ÜBAG MVZ Dr. Vehling-Kaiser GmbH Dingolfing Dingolfing, Germany
View all 18 locations
View Trial Details
Active, Not Recruiting

Obinutuzumab in Marginal Zone Lymphoma

NCT03322865

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Augusta-Kranken-Anstalt gGmbH Bochum, Germany
  • University Hospital Essen Essen, Germany
  • Universitätsklinikum Freiburg Freiburg im Breisgau, Germany
  • Universitätsmedizin Georg-August-University Göttingen, Germany
View Trial Details

Related conditions